Study guide

Universal Newborn Hearing Screening & JCIH Protocols

Praxis Audiology 5343

Track your progress as you read

Finished sections get a check mark.

1 Acoustics, Psychoacoustics & Sound Measurement

Physics of Sound, Wave Propagation & Decibel Scales (SPL, HL, SL) Psychoacoustics, Equal Loudness Contours & Frequency Selectivity Speech Acoustics, Formant Structure & Auditory Perception

2 Auditory and Vestibular Anatomy and Physiology

Peripheral Auditory System: Outer, Middle & Inner Ear Transduction Vestibular End Organs, Semicircular Canals & Otolith Mechanics Central Auditory Pathways, Neuroanatomy & Lifespan Structural Maturation Auditory Behavior, Speech-Language Development & Effects of Hearing Loss Across the Lifespan

3 Auditory Pathologies, Genetics & Instrumentation

Outer, Middle, and Inner Ear Pathologies & Genetic Syndromes Nongenetic Systemic Conditions & Infectious Causes of Hearing and Balance Disorders Ototoxic Medications, Pharmacology & Monitoring Protocols Audiometric Instrumentation, Calibration Standards (ANSI S3.6) & Psychometrics

4 Prevention, Lifespan Screening & Hearing Conservation

Universal Newborn Hearing Screening & JCIH Protocols Pediatric and School-Age Hearing Screening Procedures Adult and Geriatric Hearing Screening & Self-Assessment Measures Screening for Speech-Language, Cognitive & Other Conditions and Screening Program Performance Occupational Hearing Conservation, Noise Exposure & OSHA Regulations Hearing Health Education, Fall-Risk Identification & Audiometric and Balance Monitoring

5 Behavioral Pure-Tone Audiometry & Masking

Clinical Preparation: Case History, Otoscopy & Selecting and Modifying Tests Air and Bone Conduction Pure-Tone Testing & Audiogram Interpretation Clinical Masking Principles, Interaural Attenuation & Plateau Method Non-Organic Hearing Loss, Pseudohypacusis & Stenger Testing

6 Speech Audiometry & Pediatric Behavioral Evaluation

Speech Detection & Recognition Thresholds (SDT/SRT) & Word Recognition (WRS) Speech-in-Noise Testing, PB-Max & Retrocochlear Rollover Diagnostics Central Auditory Processing Assessment: Dichotic, Temporal, Spatial & Low-Redundancy Tests Pediatric Behavioral Audiometry: BOA, VRA, and CPA

7 Acoustic Immittance & Middle Ear Diagnostics

Tympanometric Principles, Jerger Classification & Eustachian Tube Function Acoustic Reflex Thresholds, Reflex Arc Pathways & Reflex Decay Analysis Multi-Frequency Immittance, High-Frequency Probe Tones & Infant Protocols

8 Otoacoustic Emissions & Auditory Evoked Potentials

Transient and Distortion Product Otoacoustic Emissions (TEOAE & DPOAE) Auditory Brainstem Response (ABR) Diagnostic Protocols & Wave Analysis ASSR, Electrocochleography (ECochG) & Late Auditory Evoked Potentials

9 Vestibular & Balance Assessment

Videonystagmography (VNG), Oculomotor Tracking & Positional Nystagmus Bithermal Caloric Testing, Jongkees Formula & Rotational Chair Evaluation Video Head Impulse Test (vHIT), VEMP (cVEMP/oVEMP) & Dynamic Posturography (CDP) Integrating Assessment Results, Differential Diagnosis & Reporting

10 Hearing Aid Selection, Features & Prescriptive Fitting

Treatment Planning, Goal Setting, Progress Monitoring & Intervention Documentation Hearing Aid Components, Acoustic Transducers & Digital Signal Processing Prescriptive Fitting Targets (NAL-NL2 vs. DSL m[i/o]) & Dynamic Range CROS, BiCROS & Severe-to-Profound Fitting Strategies

11 Amplification Verification, Validation & Troubleshooting

Probe-Microphone Real-Ear Verification (REUR, REAR, REIG & RECD) ANSI S3.22 Electroacoustic Analysis & Quality Control Standards Clinical Validation Inventories (COSI, APHAB, SSQ) & Device Troubleshooting

12 Implantable Devices & Hearing Assistive Technology

Bone-Conduction Systems (BAHS) & Active Middle Ear Implants Cochlear Implants: Candidacy, Telemetry, MAPping Parameters & ABI Systems Hearing Assistive Technology, FM/DM Classroom Systems & Telecoils

13 Aural Rehabilitation, Tinnitus & Vestibular Management

Adult and Pediatric Aural Rehabilitation & Communication Strategies Tinnitus Management, Sound Therapy & Decreased Sound Tolerance Protocols Canalith Repositioning Maneuvers for BPPV & Vestibular Rehabilitation Therapy (VRT)

14 Ethics, Scope of Practice & Interprofessional Collaboration

ASHA and AAA Codes of Ethics, Ethical Decision-Making & Conflict of Interest Clinical Scope of Practice, CCC-A Credentialing, Licensure & Clinical Supervision Service Delivery Models, Practice Management, Risk Management & Advocacy Patient/Family Counseling & Interprofessional Practice in Education and Healthcare

15 Regulatory Compliance, Safety & Evidence-Based Practice

Federal Regulations (HIPAA, FERPA, ADA, OSHA), Billing Compliance & Infection Control Evidence-Based Practice, Research Methodology & Teleaudiology Service Delivery

Universal Newborn Hearing Screening & JCIH Protocols

Key Takeaways Explain This Topic AI

The Joint Committee on Infant Hearing (JCIH) Year 2019 Position Statement maintains the benchmark 1-3-6 timeline (screening by 1 month, diagnostic audiological evaluation by 3 months, enrollment in early intervention by 6 months) while advancing accelerated 1-2-3 guidelines for high-capacity Early Hearing Detection and Intervention (EHDI) programs.

Screening technology selection is dictated by nursery setting: Well-Baby Nurseries may utilize either Otoacoustic Emissions (TEOAE or DPOAE) or Automated Auditory Brainstem Response (AABR), whereas JCIH recommends AABR for every infant with a NICU stay of more than 5 days.

OAE screening alone is strictly contraindicated in the NICU because outer hair cell function is preserved in Auditory Neuropathy Spectrum Disorder (ANSD), leading to catastrophic false-negative screening outcomes in high-risk neonates.

Congenital Cytomegalovirus (cCMV) is the leading non-genetic etiology of congenital and progressive sensorineural hearing loss; targeted PCR testing of saliva or urine must occur within the first 2-3 weeks of life (prior to 21 days) to distinguish congenital infection from postnatally acquired shedding.

JCIH 2019 Table 1 lists 12 risk factors with factor-specific timelines: most (for example, NICU stay over 5 days or exchange transfusion) call for diagnostic evaluation by 9 months, while ECMO, congenital CMV, meningitis, and head trauma or chemotherapy call for evaluation no later than 3 months after occurrence.

Last updated: October 2026

Universal Newborn Hearing Screening & JCIH Protocols

Universal Newborn Hearing Screening (UNHS) represents one of the most successful public health initiatives in modern medicine. Prior to the widespread adoption of UNHS, the average age of identification for congenital hearing loss was between 2.5 and 3 years, with mild-to-moderate or unilateral losses often remaining undetected until school entry. Because the critical period for central auditory pathway plasticity and primary language acquisition occurs within the first few months of life, early identification and timely intervention are essential to optimize neurodevelopmental, linguistic, and socioemotional outcomes.

The JCIH 2019 Position Statement Benchmarks: 1-3-6 vs. 1-2-3

The Joint Committee on Infant Hearing (JCIH) —an interdisciplinary committee comprising representatives from the American Academy of Audiology (AAA), the American Speech-Language-Hearing Association (ASHA), the American Academy of Pediatrics (AAP), and otolaryngology organizations—publishes definitive clinical position statements establishing standards for Early Hearing Detection and Intervention (EHDI) programs.

The Foundational 1-3-6 Mandate

The JCIH 2019 Position Statement reaffirms the internationally recognized 1-3-6 benchmark :

1 Month (Screening): All infants must undergo objective physiological hearing screening no later than 1 month of age (ideally prior to hospital discharge).

3 Months (Diagnostic Evaluation): All infants who fail (refer on) the initial screening and subsequent outpatient rescreen must complete a comprehensive diagnostic audiological evaluation (DAE) no later than 3 months of age .

6 Months (Early Intervention): All infants with confirmed permanent bilateral or unilateral hearing loss must be enrolled in specialized early intervention (EI) services under Part C of the Individuals with Disabilities Education Act (IDEA) no later than 6 months of age .

The Accelerated 1-2-3 Guidelines

In response to advances in diagnostic electrophysiology, automated data management, and the proven neuroplastic benefits of immediate intervention, the JCIH 2019 guidelines introduced an accelerated 1-2-3 benchmark for high-capacity EHDI systems that demonstrate established quality-metric compliance:

1 Month: Hearing screening completed by 1 month of age.

2 Months: Comprehensive diagnostic audiological evaluation completed by 2 months of age.

3 Months: Enrollment in individualized family service plan (IFSP) early intervention by 3 months of age.

Meeting these accelerated benchmarks enables prompt fitting of amplification (such as air-conduction or bone-conduction hearing aids) well before 3 to 4 months of age, providing acoustic stimulation during the peak window of synaptogenesis in the auditory cortex.

Screening Technologies: OAE vs. Automated ABR (AABR)

Newborn hearing screening relies exclusively on physiological, non-behavioral measures. The two objective technologies approved for newborn screening are Otoacoustic Emissions (OAE) and Automated Auditory Brainstem Response (AABR) . Each assesses a distinct anatomical locus within the auditory axis.

Feature Otoacoustic Emissions (TEOAE / DPOAE) Automated Auditory Brainstem Response (AABR)

Anatomical Locus Outer hair cells (OHC) within the Organ of Corti (pre-neural) Auditory pathway from the cochlea through 8th cranial nerve to upper brainstem

Stimulus Type Broadband clicks (TEOAE) or paired pure tones f 1 , f 2 f_1, f_2 f 1 ​ , f 2 ​ (DPOAE) Clicks or broad-spectrum frequency-chirps presented at 30 − 35 dB nHL 30 - 35\,\text{dB nHL} 30 − 35 dB nHL

Measurement Parameter Low-level acoustic emissions reflected back into external canal Surface-recorded electrophysiological potentials matched against automated template

Sensitivity Detects sensory hearing loss > 30 − 35 dB HL > 30 - 35\,\text{dB HL} > 30 − 35 dB HL Detects sensory loss and neural conduction disorders (ANSD) > 30 − 35 dB nHL > 30 - 35\,\text{dB nHL} > 30 − 35 dB nHL

Vulnerability to Debris Highly susceptible to vernix, amniotic fluid, and transient middle ear fluid Moderately resistant to mild canal debris and transient negative middle ear pressure

Test Duration Very rapid (1 to 2 minutes per ear) Slightly longer (3 to 8 minutes per ear; requires electrode montage)

Consumable Cost Lower (disposable ear tips) Higher (disposable hydrogel electrodes, snap leads, and ear tips)

Detection of ANSD Cannot detect ANSD (produces normal pass in presence of intact OHCs) Detects ANSD (manifests as refer due to abnormal or absent neural synchrony)

Transient Evoked vs. Distortion Product OAEs

Transient Evoked OAEs (TEOAEs): Generated using wideband transient clicks. TEOAEs provide broad assessment across the speech frequencies ( 1000 − 4000 Hz 1000 - 4000\,\text{Hz} 1000 − 4000 Hz ). A pass typically requires a signal-to-noise ratio (SNR) of at least 6 dB 6\,\text{dB} 6 dB across three or four discrete frequency bands, alongside total wave reproducibility > 70 % > 70\% > 70% .

Distortion Product OAEs (DPOAEs): Generated using two simultaneous pure tones ( f 1 f_1 f 1 ​ and f 2 f_2 f 2 ​ ) at fixed level ratios (typically L 1 = 65 dB SPL L_1 = 65\,\text{dB SPL} L 1 ​ = 65 dB SPL , L 2 = 55 dB SPL L_2 = 55\,\text{dB SPL} L 2 ​ = 55 dB SPL , with f 2 / f 1 ≈ 1.22 f_2 / f_1 \approx 1.22 f 2 ​ / f 1 ​ ≈ 1.22 ). DPOAEs measure the non-linear intermodulation distortion product at 2 f 1 − f 2 2f_1 - f_2 2 f 1 ​ − f 2 ​ , providing frequency-specific data up to 6000 − 8000 Hz 6000 - 8000\,\text{Hz} 6000 − 8000 Hz . A pass requires an SNR of ≥ 6 dB \ge 6\,\text{dB} ≥ 6 dB at multiple individual test frequencies.

Nursery Protocols: Well-Baby vs. NICU

A central tenet of the JCIH 2019 guidelines is that the screening protocol is strictly dictated by the infant's clinical environment and medical history.

Well-Baby Nursery Protocol

Infants in the general well-baby nursery (and NICU stays of 5 days 5\,\text{days} 5 days or less) may be screened using either OAE or AABR technology:

Initial Screen: Conducted prior to discharge, ideally after 12 to 24 hours of life to allow clearance of vernix caseosa and middle ear fluid.

Inpatient Rescreen: If the infant refers on the initial screen, a single rescreen session of both ears should be performed before discharge. Rescreening must encompass both ears, even if only one ear failed the initial test, to prevent clerical tracking errors.

Prohibition of Over-Testing ("Screening to Pass"): Repeatedly testing an infant multiple times until an incidental "pass" is recorded is strictly prohibited. Because automated screening algorithms maintain an inherent statistical false-positive rate, running serial tests will eventually generate a spurious pass by chance, resulting in missed hearing losses.

Prohibition of Inappropriate Technology Switching: If an infant fails an initial AABR screen, the screener must not switch to OAE to obtain a pass. An AABR refer reflects potential neural dyssynchrony or elevated neural thresholds that cannot be evaluated by OAE.

Neonatal Intensive Care Unit (NICU) Protocol

For any infant admitted to the NICU for more than 5 days , JCIH recommends that screening include AABR so that neural hearing loss is not missed; OAE screening alone is inadequate.

The Threat of ANSD: Infants admitted to the NICU have a markedly elevated incidence of Auditory Neuropathy Spectrum Disorder (ANSD) —accounting for up to 10% to 15% of all permanent hearing impairments in this high-acuity population. Risk factors including extreme prematurity, prolonged mechanical ventilation, hypoxia, hyperbilirubinemia, and septicemia selectively insult the inner hair cells, ribbon synapses, or auditory nerve axons while sparing outer hair cells.

Contraindication of OAE Alone: In an infant with classic ANSD, outer hair cell biomechanics remain fully intact; consequently, OAE screening yields a robust PASS , while the auditory nerve fails to transmit synchronous neural impulses to the brainstem. Screening a NICU infant with OAE alone creates a disastrous false-negative outcome.

Referral Pathway: If a NICU infant refers on the screening AABR, rescreening with OAE is completely prohibited. The infant must be referred directly to a pediatric audiologist for a comprehensive diagnostic evaluation, including frequency-specific tone-burst ABR and specialized diagnostic ABR using condensation and rarefaction clicks to evaluate for the cochlear microphonic (CM) .

Loading diagram... JCIH 2019 Newborn Hearing Screening and Follow-Up Pathway

The 12 JCIH 2019 Risk Factors and Their Follow-Up Timelines

Approximately 30% to 40% of children with congenital or early-onset hearing loss have one or more identifiable risk factors. Infants who pass the newborn screen but carry a risk factor still need a diagnostic audiological evaluation on a schedule tied to that factor. The JCIH 2019 Position Statement (Table 1) groups 12 risk factors into perinatal and perinatal-or-postnatal categories:

# JCIH 2019 Risk Factor Recommended Diagnostic Evaluation

1 Family history of early, progressive, or delayed-onset permanent childhood hearing loss By 9 months; later monitoring depends on the cause of the family hearing loss

  • 2 Neonatal intensive care of more than 5 days By 9 months
  • 3 Hyperbilirubinemia with exchange transfusion, regardless of length of stay By 9 months

4 Aminoglycoside administration for more than 5 days (shorter courses count when blood levels were toxic or a mitochondrial susceptibility such as m.1555A>G is known) By 9 months

5 Asphyxia or hypoxic-ischemic encephalopathy By 9 months

6 Extracorporeal membrane oxygenation (ECMO) No later than 3 months after occurrence, then every 12 months to school age

7 In utero infections: herpes, rubella, syphilis, and toxoplasmosis (by 9 months); congenital CMV (no later than 3 months after occurrence, then every 12 months to age 3); maternal Zika (schedule depends on infant findings) Depends on the infection

8 Certain birth conditions: craniofacial malformations (microtia/atresia, ear dysplasia, oral-facial clefting, white forelock, microphthalmia), congenital microcephaly, congenital or acquired hydrocephalus, temporal bone abnormalities By 9 months

9 Syndromes associated with atypical hearing thresholds (more than 400 identified) By 9 months, then according to the syndrome's natural history

10 Culture-positive infections associated with sensorineural loss, including confirmed bacterial or viral (especially herpes virus and varicella) meningitis or encephalitis No later than 3 months after occurrence, then every 12 months to school age

11 Events associated with hearing loss: significant head trauma (especially basal skull or temporal bone fracture) or chemotherapy No later than 3 months after occurrence

12 Caregiver concern about hearing, speech, language, development, or developmental regression Immediate referral

Exam pearls tied to specific factors:

Congenital CMV is the most common non-genetic cause of childhood sensorineural hearing loss. Its loss can be delayed-onset, fluctuating, or progressive, which is why it carries the tightest surveillance schedule.

ECMO and meningitis carry high risk of rapidly progressive loss. Meningitis can trigger labyrinthitis ossificans , so a new profound loss after meningitis needs urgent cochlear implant referral.

Hyperbilirubinemia requiring exchange transfusion is the one factor that counts regardless of NICU length of stay; kernicterus preferentially injures auditory brainstem nuclei and can produce ANSD.

Isolated preauricular pits and tags were removed as a risk factor in 2019 because they show no higher reported incidence of hearing loss than in other children.

Syndromes to recognize include Pendred (enlarged vestibular aqueduct, goiter), Usher (retinitis pigmentosa), Waardenburg (pigmentary changes), Jervell and Lange-Nielsen (long QT), and Treacher Collins (craniofacial anomalies with conductive loss).

Targeted Congenital Cytomegalovirus (cCMV) Protocols

Cytomegalovirus is a double-stranded DNA herpesvirus and represents the single leading non-genetic cause of congenital sensorineural hearing loss in developed nations. Approximately 1 in 200 infants is born with congenital CMV, and up to 15% to 20% of infected children develop permanent sensorineural hearing loss.

The Critical Diagnostic Window ( < 21 Days < 21\,\text{Days} < 21 Days )

A fundamental clinical principle tested on board examinations is the strict timing requirement for diagnosing congenital CMV:

Saliva or Urine Real-Time PCR: Testing must be completed within the first 2 to 3 weeks of life (prior to 21 days) .

Clinical Rationale: Beyond 21 days of life, shedding of CMV DNA in urine or saliva can no longer be distinguished from postnatally acquired infection (e.g., transmission via breastmilk, maternal cervical secretions during birth, or contact with siblings). Postnatally acquired CMV in full-term infants is benign and does not cause progressive sensorineural hearing loss or neurodevelopmental sequelae.

Targeted vs. Universal Screening: While universal screening is expanding, most hospital systems utilize targeted CMV screening —triggering saliva PCR testing immediately whenever an infant refers on their newborn hearing screen in either ear.

Audiological Profile & Antiviral Management

Audiometric Presentation: cCMV-induced hearing loss is notoriously unpredictable. It can be unilateral or bilateral, ranges from mild to profound, and frequently exhibits delayed onset (months to years after birth) and fluctuating or progressive configurations.

Medical Intervention: Oral valganciclovir initiated within the first month of life for symptomatic or hearing-targeted congenital CMV has been shown to arrest hearing deterioration and improve neurodevelopmental outcomes, underscoring the urgency of rapid diagnostic confirmation.

Lost-to-Follow-up (LTFU) Mitigation & Parental Communication

The most significant systemic challenge facing EHDI programs globally is loss to follow-up (LTFU) or loss to documentation (LTD). Historically, between 30% and 50% of infants who failed newborn hearing screenings failed to receive documented diagnostic audiological evaluations within the mandated 3-month window.

Systemic Mitigation Strategies

Direct Appointment Scheduling: Scheduling the diagnostic audiological evaluation before the mother and infant are discharged from the maternity unit dramatically reduces LTFU rates.

State EHDI Tracking Registries: Automated electronic health record (EHR) cross-matching directly notifies state public health departments of screening results, triggering automated tracking workflows.

Medical Home Engagement: Designating the primary care physician (pediatrician or family medicine practitioner) as the central care coordinator ensures screening results are addressed at the 2-week and 1-month well-child visits.

Evidence-Based Parental Communication

The language utilized by hospital screeners when an infant does not pass the screening directly impacts parental follow-up adherence and maternal mental health:

Avoid False Reassurance: Never dismiss a refer result with statements such as "It's almost certainly just fluid or vernix in the ear, so don't worry about it." Such statements lead parents to skip recommended diagnostic appointments.

Avoid Alarmist Catastrophizing: Never inform parents that "Your baby failed the test and is deaf." Screening instruments do not diagnose hearing loss; they identify the need for diagnostic evaluation.

Standardized Messaging: Clinical guidelines recommend clear, objective phrasing: "Your baby did not pass the hearing screening today in one/both ears. This does not mean your baby has permanent hearing loss, but it does mean your baby needs a specialized follow-up diagnostic test with an audiologist before 3 months of age to determine how they hear."

Clinical Traps & Exam Pearls

Warning

The NICU OAE Trap: The most frequent exam trap involves a question presenting an infant who spent 10 days in the NICU on assisted ventilation, where a screener conducts an OAE test, records a "pass," and discharges the infant. This is a severe clinical error. NICU infants with stays of more than 5 days need an AABR to rule out ANSD; a normal OAE in this scenario provides false reassurance while missing life-altering neural hearing impairment.

Important

The Postnatal CMV Window: A 6-week-old infant fails an outpatient hearing evaluation, and a saliva PCR test is ordered, returning positive for CMV. Board questions will ask if this confirms congenital CMV. It does not. Because the sample was obtained after 21 days of life, it may reflect postnatally acquired viral shedding (e.g., from breastmilk). Congenital confirmation requires testing dried blood spots (Guthrie card) stored from the newborn metabolic screen.